UBS O'Connor’s NeoGenomics NEO Stock Holding History

UBS O'Connor’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-68,750	Closed	-$1.51M	–	347
2019 Q2	$1.51M	Buy	+68,750	New	+$1.51M	0.03%	156

Other funds holding NEO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

CTA

Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

GIP

Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

UBS O'Connor's NEO Position: Q3 2019 in Review

UBS O'Connor sold out of NeoGenomics (NEO) in Q3 2019, closing a stake of 68,750 shares — an estimated $1.51M sold.

UBS O'Connor first reported a position in NEO in Q2 2019 and held it in 1 quarter. The position peaked at $1.51M in Q2 2019. 253 funds tracked by Wall St. Rank hold NEO as of Q3 2019.

UBS O'Connor reported no remaining NeoGenomics position as of Q3 2019 after selling out during the quarter.
UBS O'Connor sold 68,750 NeoGenomics shares in Q3 2019, an estimated $1.51M.
UBS O'Connor first reported a position in NeoGenomics in Q2 2019 and held it in 1 quarter.
UBS O'Connor's NeoGenomics position peaked at $1.51M in Q2 2019.
253 funds tracked by Wall St. Rank held NeoGenomics as of Q3 2019.

Based on UBS O'Connor's 13F filing for Q3 2019, filed 14 Nov 2019.